



Background

ar and En

- Extensive review of both radiofrequency and laser venous ablation procedures have demonstrated excellent treatment effectiveness and durability for each modality.
- However, there is less data regarding treatment effectiveness and durability for these procedures in patients who are also on systemic anticoagulation – warfarin or DOACs.

Modalities of Thermal Ablation

•RFA

•Endothermal Laser Ablation

Authors	Mode of Ablation	Number of Subjects	Follow up	% with durable ablation
Golan and Glenn (2008)	RF- 1006 EVLA - 499	1,505	RF – 5 yrs EVLA – 17 mos	87% 98%
Christenson et al (2010)	EVLA	104	2 yrs	95%
Merchant and Pichot (2005)	RFA	1,222	5 years	87%

Authors	Mode of Ablation	Number of Subjects	Follow up	% with durable ablation	Bleeding/ complications
Sharifi et al (2011)	RFA – 48 EVLA - 40	88	1 year	RF- 100% EVLA-100%	9% (minor)
Theivacumar et al (2009)	EVLA	22	1 year	83% (vs 96% control)	none
Gabriel et al (2012)		59 gsv/ssv - with perf	72 hrs	100 (%) (effective)	4% (minor)
Riesenman et al (2011)	EVLA	12	8 weeks	100%	none
Sufian et al (2017)	EVLA/RF	375	30 days	90%	minor

1

Effectiveness and Durability of Thermal Ablation on Anticoagulation (warfarin)					
Authors	Mode of Ablation	Number of Treated Veins	Follow up	% with durable ablation	Bleeding/ complications
Sharifi et al (2011)	RFA – 48 EVLA - 40	88	1 year	RF- 100% EVLA-100%	9% (minor)
Theivacumar et al (2009)	EVLA	22	1 year	83% (vs 96% control)	none
Gabriel et al (2012)		59 gsv/ssv - with perf	72 hrs	100 (%) (effective)	4% (minor)
Riesenman et al (2011)	EVLA	12	8 weeks	100%	none
Sufian et al (2017)	EVLA/RF	375	30 days	90%	minor
NYU 2017	RFA - 50 EVLA - 50	100	18 months	RF/EVLA 92% RF/EVLA 89%	none
			24-36 mos		





Objective

To evaluate the efficacy, durability, and safety of radiofrequency (RFA) and endovenous laser (EVLA) ablation of the great saphenous and small saphenous veins to treat symptomatic venous reflux in patients on therapeutic anticoagulation with DOACs

Methods and Definitions

-Data was collected from a single-center institution (NYU Langone Health) -patients who had undergone either radiofrequency ablation or laser ablation procedures between **2016 and 2020**.

87 vessels of patients (69 patients) on **DOAC** therapy at the time of endothermal ablation were selected for study. (largest to date). DOAC included apixaban 45%, Rivaraxaban 39%, Dabigatran (13%) and edoxaban (3%)

This group was compared to a matched group of **232** vessels (295 patients) undergoing endothermal ablation in patients not on anticoagulation

12







Methods

•Follow-up with duplex ultrasound at 1 week post-procedure, 6 months, 1 year



Results

Veins treated with DOAC GSV 66 (76%), SSV 21 (24%) ns Veins treated control - GSV 247(84%, SSV 48 (16%) ns

Vein max diameter 8mm both groups (NS)

Vein treatment length DOAC 35mm, Control 38mm (NS) Indications for anticoagulation similar – afib (most common) , remote DVT

DOAC pts - older 65 v 55 yrs (P<.001) higher incidence previous DVT (44% vs 6%) (p<.001)

Mean VCSS, proportion of obesity distribution of race/ethnicity - ns

18







Effectiveness and Durability of Thermal Ablation on Anticoagulation (warfarin and DOAC)					
Authors	Mode of Ablation	Number of Treated Veins	Follow up	% with durable ablation	Bleeding/ complications
Sharifi et al (2011)	RFA – 48 EVLA - 40	88	1 year	RF- 100% EVLA-100%	9% (minor)
Theivacumar et al (2009)	EVLA	22	1 year	83%	none
Gabriel et al (2012)		59 gsv/ssv - with perf	72 hrs	100 (%) (effective)	4% (minor)
Riesenman et al (2011)	EVLA	12	8 weeks	100%	none
Sufian et al (2017)	EVLA/RF	375	30 days	90%	minor
NYU 2017 (warfarin)	RFA - 50 EVLA - 50	100	18 months 24-36 mos	RF/EVLA 92% RF/EVLA 89%	none
NYU 2021 (DOAC)	RF/EVLA	87	9 months	94%	none



